about
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disordersPropagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.Progression of dysprosody in Parkinson's disease over time--a longitudinal studyThe locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural studyAutomatic Evaluation of Speech Rhythm Instability and Acceleration in Dysarthrias Associated with Basal Ganglia DysfunctionCalbindin controls release probability in ventral tegmental area dopamine neurons.Semantic processing deficits in patients with Parkinson's disease: degraded representation or defective retrieval?Cortical control of saccades in Parkinson disease and essential tremor.Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicitySerotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data.Entacapone.Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis.An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicityStaging neurodegenerative disorders: structural, regional, biomarker, and functional progressions.Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson's disease.Localization and function of dopamine receptors in the subthalamic nucleus of normal and parkinsonian monkeys.The Wld(S) mutation delays anterograde, but not retrograde, axonal degeneration of the dopaminergic nigro-striatal pathway in vivo.Subregional 6-[18F]fluoro-ʟ-m-tyrosine uptake in the striatum in Parkinson's disease.Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's diseaseClinical progression in Parkinson disease and the neurobiology of axons.Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia.Personality traits in young patients with Parkinson's disease.Noradrenaline-induced release of newly-synthesized accumbal dopamine: differential role of alpha- and beta-adrenoceptors.Extrastriatal dopaminergic circuits of the Basal Ganglia.Modeling the contributions of Basal ganglia and Hippocampus to spatial navigation using reinforcement learningThe influence of dopaminergic striatal innervation on upper limb locomotor synergies.5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy.Altered basal and stimulated accumbens dopamine release in obese OLETF rats as a function of age and diabetic status.Striatal glutamatergic mechanisms and extrapyramidal movement disorders.Nigral dopamine loss induces a global upregulation of presynaptic dopamine D1 receptor facilitation of the striatonigral GABAergic outputDistribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies.Axon degeneration in Parkinson's diseaseThalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptomsNovel multifunctional pharmacology of lobinaline, the major alkaloid from Lobelia cardinalis.Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.Heterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain.Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.Premotor biomarkers for Parkinson's disease - a promising direction of research.
P2860
Q26826093-B74CDF83-55E6-4319-A1C8-26B8C692D4C0Q27322513-C13D2173-E652-4A0E-AAE7-07D918D82F39Q28305419-45404389-6F2F-4210-A0D2-8DEE80F7D5E5Q28477041-BA316C5A-5CBF-40D9-BF2F-2EC61720DB1AQ30405128-AD90515C-6FFF-4A3E-B256-E6A4CC38265CQ30452597-303C2F25-6352-400F-BB5B-FC02BA2E141BQ30498974-53F42969-0ED1-4E2B-9103-6E3318A966ABQ30559517-AD89822B-D848-451D-B5BF-31C5D94C5AA2Q30577415-3F85671E-24CA-4A97-8375-42E387562DD0Q31013566-7196014B-E38D-4682-A09E-DBDE7ED95946Q31440112-9CA1957A-5D83-48D2-BA3A-34BE95E807FAQ32052296-9215DE3F-DFD2-468B-B39D-D01BEA7F8E44Q33317678-DCFE5B86-EF11-443A-8EED-2645B1D69115Q33556006-C60B7613-9BF1-40F4-9ABB-FD98CEFB8BACQ33633995-06B8D26E-9294-49E0-9D72-1DBDFBD5A35CQ33781476-62B16D2F-3117-4E56-98FB-0736B032E17BQ33841702-50A11B3F-0C6F-4ED2-9BDB-033CCA275C15Q33853332-A0B150FC-2042-4CD1-BBB2-E265ACAEE178Q33896138-1D840C3A-A5F9-46C1-BE8B-E2CA7E773ECEQ33944220-0FE721DE-D885-4BF1-AD29-84F481DBA3BDQ34052764-68523A3E-8F19-4141-9DBC-AF48B297A17BQ34098776-706FAA3B-B8CE-485E-BEC6-CBD01A227F94Q34167267-219EC65C-8F8A-494A-81BE-23E0259403C4Q34171671-87BB7AA8-172E-4D5D-96CB-E849B0ECD235Q34330022-6A4664C2-A30F-4302-BF24-C49FBB2D9FF7Q34460428-80828EC3-1DB5-4493-8D8B-71697E4330E2Q34511022-CD245CDF-7E87-404C-B014-BFE9C750A58FQ35015786-43EF233F-92CC-4498-A5F9-40BB0B9A318AQ35043538-43380C40-F3C3-490F-BBAC-020192039984Q35165439-348B2B5C-C8E4-43FB-9C39-BF93090DF89FQ35178497-C6DC0513-E5AE-4469-95CF-0755FCCA7A1CQ35524103-C5039250-6BCE-44D6-9A54-B5F62124DDE7Q35923102-9FAE8D55-80DC-4240-A1C8-C1C3816E0FDCQ35942601-B8442443-13D9-4BE9-A29C-FD8F7051E6A0Q35997207-19B60F09-DD21-4900-89A2-A39857E53AE6Q36040754-A6DEC97F-3CE6-4EAC-A7CF-F28D2DD37CC2Q36041480-D7C6F722-8AE3-4A02-8351-E7BA17AEDC6AQ36185625-00594827-8607-4EC6-AF23-9D38281787A5Q36200063-0B83413E-6795-4762-AF5A-9B30E0D43502Q36444517-F81DB478-656A-4878-A800-1429C6492D3F
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Biochemical aspects of Parkinson's disease.
@en
Biochemical aspects of Parkinson's disease.
@nl
type
label
Biochemical aspects of Parkinson's disease.
@en
Biochemical aspects of Parkinson's disease.
@nl
prefLabel
Biochemical aspects of Parkinson's disease.
@en
Biochemical aspects of Parkinson's disease.
@nl
P1433
P1476
Biochemical aspects of Parkinson's disease.
@en
P2093
Hornykiewicz O
P356
10.1212/WNL.51.2_SUPPL_2.S2
P407
P433
P577
1998-08-01T00:00:00Z